01 2BRISTOL
02 38GILEAD SCIENCES INC
03 19JANSSEN PRODS
01 310039718*PED
02 27176220
03 610039718
04 110786518
05 27176220*PED
06 27390791
07 17390791*PED
08 27635704
09 27635704*PED
10 27700645
11 17700645*PED
12 128148374
13 38148374*PED
14 28633219
15 28633219*PED
16 38754065
17 18754065*PED
18 28981103
19 28981103*PED
20 39296769
21 19296769*PED
22 29891239
23 29891239*PED
01 28Y
02 31Blank
01 38Y
02 21Blank
01 12025-01-07
02 12025-04-17
03 12025-07-07
04 22026-08-27
05 42026-10-26
06 22026-12-26
07 22027-02-27
08 42027-04-26
09 12027-06-26
10 142029-09-03
11 52030-03-03
12 22030-04-30
13 22030-10-30
14 62032-08-15
15 62032-10-06
16 22033-02-15
17 32033-04-06
18 12038-07-19
Patent Expiration Date : 2029-09-03
ATAZANAVIR SULFATE; COBICISTAT
US Patent Number : 8148374
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 206353
Patent Use Code : U-1279
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2029-09-03
Patent Expiration Date : 2032-10-06
ATAZANAVIR SULFATE; COBICISTAT
US Patent Number : 10039718
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 206353
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-10-06
Patent Expiration Date : 2030-04-30
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 8633219
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2030-04-30
Patent Expiration Date : 2026-10-26
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 7635704
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2026-10-26
Patent Expiration Date : 2029-09-03
US Patent Number : 8148374
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 203094
Patent Use Code : U-1279
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2029-09-03
Patent Expiration Date : 2029-09-03
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 8148374
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-1279
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2029-09-03
Patent Expiration Date : 2032-08-15
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 8754065
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2032-08-15
Patent Expiration Date : 2032-08-15
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 9296769
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2032-08-15
Patent Expiration Date : 2029-09-03
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 9891239
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2029-09-03
Patent Expiration Date : 2030-04-30
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 8633219
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2030-04-30
